Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc., a life sciences company, focuses on developing and commercializing proprietary broad-based technologies in medical and consumer healthcare markets. It specializes in the research and development of biomedical products and devices for antibacterial applications. The company's core technologies include Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS), a family of advanced polymers with antimicrobial, hemostatic, and other properties for use in a range of applications; Stay Fresh, a chemical formulation for textiles with a durable antimicrobial agent effective against an array of bacteria; and MultiStat, a family of advanced patented methods and compounds effective in skin therapy applications. It serves government agencies; and healthcare and medical, apparel and textile, and personal care companies. The company was founded in 1997 and is headquartered in Gainesville, Florida.

Quick-Med Technologies, Inc. trades as QMDT on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Quick-Med Technologies, Inc. can be compared against peers such as CanaQuest Medical Corp., Ventura Cannabis & Wellness Corporation, Deltagen Inc., Emergent Health Corp, Net Medical Xpress Solutions, Inc., NxGen Brands Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $29,877, beta of -39.80, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

QMDT currently shows total debt of N/A and beta of -39.80. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.quickmedtech.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.